Key Insights on the Impact of Sacubitril–Valsartan in Canada, Despite Limitations of Registry Data Authors: Michael A McDonald, Melanie Kok, Anique Ducharme, Justin Ezekowitz, Jonathan Howlett, Carlos Rojas-Fernandez, Jacob A Udell Published: 2026 We appreciate the opportunity to respond to Dr. Aydin’s letter regarding the methodological concerns with respect to our recently published Patient Registry Assessing Effectiveness and Safety of Heart Failure Treatment with LCZ696 Across Canada (PARTHENON Registry) study. We sought to characterize the clinical course and safety of patients with heart failure (HF) and reduced ejection fraction (HFrEF) initiated on sacubitril-valsartan in the Canadian context. We agree that our study does have limitations that are expected for any naturalistic, noninterventional, observational study. Indeed, only 35% (339 of 996) of our patients had baseline natriuretic peptide (NP) testing. As noted in our Discussion, this percentage precludes making definitive conclusions on the relationship between baseline NP levels and HF outcomes in a Canadian HFrEF population starting sacubitril–valsartan therapy. Our findings also highlight the variable access to NP testing in Canada, and data from the PARTHENON Registry provides some reassurance that sacubitril–valsartan is safe, well-tolerated, and effective irrespective of baseline NP testing. Although a comparison of observed mortality vs risk-model predicted mortality in our study (using the Seattle HF Model and the Meta-Analysis Global Group in Chronic Heart Failure [MAGGIC] score) was intended to provide helpful context as an outcome of interest, we recognize the potential limitations with this approach, particularly as these risk models were developed prior to the modern era of guideline directed medical therapy (GDMT). However, an important point to note is that these risk scores are still well calibrated to contemporary cohorts of patients with HF.1,2 In addition, only a minority of patients with HFrEF in Canada are actually treated with 3 GDMT medications, and a recent study found that only ∼13% are optimized on GDMT within 6 months following a HF hospitalization.3 We believe that the comparison of outcomes between PARTHENON Registry patients and risk-score predicted outcomes is instructive for contemporary HF care. Finally, we concede that our study design may have introduced potential survivor bias (as we could have excluded patients that died early following sacubitril–valsartan initiation prior to registry enrollment). However, in the opinion of the investigators, this potential bias would be very unlikely to have impacted our results, as most participants were approached for study enrollment at the time of initial sacubitril–valsartan prescription. Funding Sources The PARTHENON Study was funded by Novartis Pharmaceuticals Canada, Inc. Disclosures M.A.M. reports receiving honoraria/speaker fees from Novartis & Servier; serving as a consultant or on an advisory board for Novartis, BI-Lilly, and Bayer; and receiving a research grant from Novartis. A.D. reports receiving speaker bureau/ad board honoraria from Abbott, Alnylam, Astra-Zeneca, Bayer, Boehringer-Ingelheim, Novartis, and Pfizer; and receiving research support and/or grants from Abbott, Astra-Zeneca, Bayer, Corvia, BridgeBio, Merck, Novartis, Novo Nordisk, and Pfizer. J.E. reports receiving research support for trial leadership from Bayer, Merck & Co, Novo Nordisk, Cytokinetics, Applied Therapeutics, and American Regent; and receiving honoraria for consultancy from AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Otsuka, Bayer, and Novartis. J.H. reports receiving honoraria and/or speaker fees from Amgen, AstraZeneca, BI, Bayer/Merck, Novartis, Novo Nordisk, and Pfizer; and serving as a consultant or an on advisory board for and receiving grants or contracts from Amgen, AstraZeneca, BI, Novartis, Novo Nordisk, and Pfizer. M.K. and C.R.-F. are employed by Novartis. J.A.U. reports receiving speaker and/or consulting honoraria from Amgen, Boehringer Ingelheim, Janssen, Merck, Novartis, and Sanofi; and grant support to his institutions from AstraZeneca, Bayer, Boehringer Ingelheim, Janssen, Novartis, and Sanofi. References